RAPID BACTERIAL DETECTION METHODS FOR PLATELETS. M. Schmidt
|
|
|
- Agnes Gallagher
- 6 years ago
- Views:
Transcription
1 RAPID BACTERIAL DETECTION METHODS FOR PLATELETS M. Schmidt Deutsches Rotes Kreuz Blutspendedienst Baden-Württemberg-Hessen Goethe Universität Frankfurt am Main Institut für Transfusionsmedizin und Immunhämatologie
2 Schrezenmeier et al Transfusion, 2007;47: Hourfar et al Transfusion, 2008;48: Rapid bacterial detection methods for platelets 2 German Red Cross bacteria and virus study Bacterial risks Viral risks Contaminated platelets 1:1.428 Septic reactions 1: HBV HCV HIV 1 : 360,000 (CI: million) 1 : million ( million) 1 : 4.3 million ( million)
3 Fatalities due to transmission of bacteria 4x PRC, 4xAPC, 4xPPC 3 Anzahl der Fälle (n) Fraglicher Fall Bestätigter Fall Tod des Empfänger durch Transfusion von EKs Tod des Empfängers durch Transfusion von TKs Funk et al Transfus Med Hemoth, 2011 Jahre
4 Funk et al Transfus Med Hemoth, 2011 Rapid bacterial detection methods for platelets Bacteria strains in blood components 4 PRC storage temperature 2-10 C PC storage temperature 21 C 6/8 contaminated PCs were transfused at the end of shelf life Strains in PRCs: Serratia marcenses Staphylococcus aureus Yersinia enterocolitica (2 cases) Strains in PCs: Klebsiella pneumoniae (2 cases) Staphylococcus aureus Staphylococcus epidermidis Streptococcus pyogenes (3 cases) Enterococcus cloacae
5 Schmidt et al Manuscript in preparation Rapid bacterial detection methods for platelets Growth kinetics of K pneumoniae 5 Growth kinetics in PRCs Growth kinetics in PCs Bacterial concentration in CFU/ml time (h) Bacterial concentration in CFU/ml time (h)
6 Votum 38 working group blood Reduction of platelet shelf life to 4 days
7 Dreier et al Clinical Chemistry, 2009 Rapid bacterial detection methods for platelets 7 First description of bactiflow
8 8 Investigation of pool platelets and apheresis platelets on day 3, day 4 and day 5 after spiking with BacT/ALERT, Bactiflow, inhouse FACS and 16s DNA NAT Spiking day 1 day 2 day 3 day 4 day 5 Time (days) W. Sireis Vox Sanguinins 2011
9 9 Results Bactiflow with apheresis platelets Counts (n) Decision line A B C A B C A B C A B C A B C A B C A B C K. pneumoniae (PEI) K. pneumoniae (GRC) S. epidermidis S. aureus S. pyogenes B. cereus S. marcescens W. Sireis Vox Sanguinins 2011
10 10 Results BacT/ALERT with apheresis platelets Maximum incubation time in BacT/ALERT Time (h) A B C A B C A B C A B C A B C A B C A B C K. pneumoniae (PEI) K. pneumoniae (GRC) S. epidermidis S. aureus S. pyogenes B. cereus S. marcescens W. Sireis Vox Sanguinins 2011
11 11 Comparison of all results with rapid bacterial detection systems for pool platelets BacT/ALERT Bactiflow FACS method 16s DNA method Bacterial strains Day 3 Day 4 Day 5 Day 3 Day 4 Day 5 Day 3 Day 4 Day 5 Day 3 Day 4 Day 5 K. pneumoniae PEI K. pneumoniae BRC S. epidermidis 7 / 10 8 / 10 S. aureus 0 / 10 9 / 10 9 / 10 S. pyogenes 9 / 10 7 / 10 3 / 10 2 / 10 9 / 10 B. cereus 8 / 8 8 / 8 8 / 8 8 / 8 8 / 8 8 / 8 8 / 8 8 / 8 8 / 8 8 / 8 8 / 8 8 / 8 S. marcescens W. Sireis Vox Sanguinins 2011
12 12 Comparison of all results with rapid bacterial detection systems for apheresis platelets W. Sireis Vox Sanguinins 2011
13 13 Zelos x100 extraction system
14 Comparison of automated NAT systems 14
15 Description of screening process: Pooling (up to 10 samples per pool) 15 Extraction Zelos x100 Amplification ABI 7500
16 German Red Cross BAK PCR Kit POS controls: 16
17 German Red Cross BAK PCR Kit Internal controls: 17
18 18 Investigation of pool platelets and apheresis platelets on day 2, day 3 and day 4 after spiking with 16s DNA NAT Spiking day 1 day 2 day 3 day 4 Time (days)
19 19 Data for buffy coat derived minipool platelets ID-NAT MP-NAT with pools of 5 samples MP-NAT with pools of 10 samples Bacterial strain day 2 day 3 day 4 day 2 day 3 day 4 day 2 day 3 day 4 K. pneumoniae 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/10 K. pneumoniae Bayern 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/10 S. epidermidis 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/10 S. aureus 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/10 S. pyogenes 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/10 B. cereus 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/10 S. marcesens 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/10
20 20 Data for apheresis platelets ID-NAT MP-NAT with pools of 5 samples MP-NAT with pools of 10 samples Bacterial strain day 2 day 3 day 4 day 2 day 3 day 4 day 2 day 3 day 4 K. pneumoniae 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 K. pneumoniae Bayern 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 S. epidermidis 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 S. aureus 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 S. pyogenes 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 B. cereus 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 S. marcesens 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5 5/5
21 Specificity of the German Red Cross bacteria NAT system 21 Specificity was investigated for buffy coat derived minipool platelets as well as for apheresis platelets on individual samples (volume 6ml) Samples were collected at the end of platelet shelf life Buffy coat derived minipool - platelets Apheresis platelets Total number of products Initial reactive products 0 0 confirmed reactive products 0 0 confirmed positive products 0 0 Specificity >99,5% >99,5%
22 PCR/Bactiflow PCR 4 5 BacT/ALERT without screening Donation day 1 after donation day 2 after donation day 3 day 4 after after donation donation Time (days) day 5 after donation day 6 after donation
23 Issue of PCs in BDS Baden-Württemberg - Hessen 23 Schrezenmeier et al. Transfusion 2007;47:644
24 Data bacterial screening since October Total number of investigation (N) (34,4%) Platelets shelf life extended Platelets released on day 5 Platelets discarded on day 6
25 Data bacterial screening Bactiflow (IR app. 2%) 25 30" 25" Total number tested 2,050 platelets No confirmed reactive samples 20" 15" 10" ULM" OST" FFM" MA" Gesamt" 5" 0" IR" IR"(%)" WR" WR"(%)"
26 Data bacterial screening NAT (IR app. 0.2%) 26 2,5" 2" FFM#PCR# Total number tested 1,045 platelets No confirmed reactive samples 1,5" 1" FFM"PCR" 0,5" 0" IR" IR"(%)" WR" WR"(%)"
27 27 Diversion of the first 30 to 40 ml TIME (days)
28 28 Diversion of the first 30 to 40 ml Strategy 1: Culture tests in combinafon with the negafve- to- date concept TIME (days)
29 29 Diversion of the first 30 to 40 ml Strategy 2: Pathogen reducfon methods Strategy 1: Culture tests in combinafon with the negafve- to- date concept TIME (days)
30 30 Diversion of the first 30 to 40 ml Strategy 3: Release on day 1 and day 2 aler donafon without tesfng Strategy 2: Pathogen reducfon methods Rapid bacterial detecfon systems on day 3 Strategy 1: Culture tests in combinafon with the negafve- to- date concept TIME (days)
31 31 Diversion of the first 30 to 40 ml Strategy 4: ReducFon of platelet shelf life Strategy 3: Release on day 1 and day 2 aler donafon without tesfng Strategy 2: Pathogen reducfon methods Rapid bacterial detecfon systems on day 3 Strategy 1: Culture tests in combinafon with the negafve- to- date concept TIME (days)
32 Acknowledgement 32 E. Seifried W. Sireis B. Rüster M.K. Hourfar K. Gubbe G. Capalbo U. Mayr-Wohlfart U.M. Liebscher H. Schrezenmeier H. Klüter M. Heiden E.-M. Schneider T. Montag M. Störmer M. Nübling
BACTERIAL INTERVENTIONS TO INCREASE BLOOD SAFETY
BACTERIAL INTERVENTIONS TO INCREASE BLOOD SAFETY Jennifer Allen National Bacteriology Laboratory on behalf of Dr. C P McDonald Head of Bacteriology National Bacteriology Laboratory NHSBT Klebsiella oxytoca
Update on THERAFLEX UV-Platelets: a novel system for pathogen reduction of platelets
Update on THERAFLEX UV-Platelets: a novel system for pathogen reduction of platelets Axel Seltsam, MD, MHBA German Red Cross Blood Service NSTOB, Springe Fribourg 2011 THERAFLEX UV-Platelets Efficient
Pathogenreduktion mittels UVC-Licht: Entwicklung des THERAFLEX UV-Plättchen-Systems
Pathogenreduktion mittels UVC-Licht: Entwicklung des THERAFLEX UV-Plättchen-Systems Pathogen reduction by UVC light: Development of the THERAFLEX UV-Platelets system Fribourg 2011 Prof. Dr. Axel Seltsam,
Bacterial Screening of Platelet Concentrates
Bacterial Screening of Platelet Concentrates Enda Cadden Platelet Donations Very Short shelf-life
Pathogen Reduction/Inactivation KABB Annual Meeting Elpidio Pena, MD, MA Norton Healthcare Transfusion Services
Pathogen Reduction/Inactivation KABB Annual Meeting 2017 Elpidio Pena, MD, MA Norton Healthcare Transfusion Services Goals Discuss the approved methods for pathogen reduction/inactivation of blood products
KNOWLEDGE INFUSION: FOCUS ON AABB 2016
KNOWLEDGE INFUSION: FOCUS ON AABB 06 Permission to Use: Please note that the presenter has agreed to make their presentation available. However, should you want to use some of the data or slides for your
Optimal / Evidence-based Method to Prevent Transmission of Cytomegalovirus (CMV) by Transfusion
ILABB Fall Meeting 2015 Optimal / Evidence-based Method to Prevent Transmission of Cytomegalovirus (CMV) by Transfusion Presenter Ronald G Strauss, MD Associate Medical Director, LifeSource/ITxM Terms
Impact of donor epidemiology and screening strategies on the safety of blood and plasma for fractionation
IPFA 2 nd Asia Workshop in Yogyakarta Impact of donor epidemiology and screening strategies on the safety of blood and plasma for fractionation Yoshihiko Tani, MD, PhD Japanese Red Cross Osaka Blood Center
Storage medium and transfusion transmitted bacterial infections
Storage medium and transfusion transmitted bacterial infections Aukje Kreuger Phd Student Center for Clinical Transfusion Research, Sanquin, Leiden Department of Epidemiology, LUMC, Leiden TTIP meeting,
R Offergeld, D Faensen, S Ritter, O Hamouda Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
Eurosurveillance, Volume 10, Issue 2, 01 February 2005 Surveillance report HUMAN IMMUNODEFICIENCY VIRUS, HEPATITIS C AND HEPATITIS B INFECTIONS AMONG BLOOD DONORS IN GERMANY 2000-2002: RISK OF VIRUS TRANSMISSION
Source of platelet concentrates FACHBEREICH MEDIZIN
FACHBEREICH MEDIZIN Efficacy and safety of platelet concentrates from platelet apheresis donations or whole blood donations Gregor Bein Institute for Clinical Immunology and Transfusion Medicine Justus-Liebig-University
Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey
Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey This questionnaire consists of three sections: A. Collection and
Annual SHOT Report 2016 Supplementary Information. Chapter 17: Transfusion-Transmitted Infections (TTI)
Annual SHOT Report 2016 Supplementary Information Chapter 17: Transfusion-Transmitted s (TTI) The table below is an excerpt from the full Table 17.3 which can be viewed in the main report. Case reports
Khalid Alquthami (Correspondence) Regional Lab, Makkah. Saudi Arabia
1 Regional Lab, Makkah. Saudi Arabia stract: Clinical specificity and genotype/subtype detection of viruses using the Cobas TaqScreen MPX system V 2.0, which is a nucleic acid test (NAT) that uses multiples
Ergebnisse der Abfrage zu NAT-only positiven Befunden beim Blutspendescreening (NAT yield) Micha Nübling, PEI
Ergebnisse der Abfrage zu NAT-only positiven Befunden beim Blutspendescreening (NAT yield) Micha Nübling, PEI NAT for cellular blood components in Germany Definition of minimal NAT sensitivity limit (ID)
Chapter 17: Transfusion-Transmitted Infections (TTI)
Annual SHOT Report 2014 Supplementary Information Chapter 17: Transfusion-Transmitted s (TTI) The table below is an excerpt from the full Table 17.2 which can be viewed in the main report. Case reports
Impact of multi-dye multiplex technology on testing algorithm
Impact of multi-dye multiplex technology on testing algorithm Lydia Blanco. Mª Isabel Gonzalez-Fraile Centro de Hemoterapia y Hemodonación de Castilla y León, España TTI EPIDEMIOLOGICAL DATA IN SPAIN NAT
Versorgungsforschung in Deutschland Der Beitrag der Transfusionsmedizin. Health Services Research in Germany The Input of Transfusion Medicine
Versorgungsforschung in Deutschland Der Beitrag der Transfusionsmedizin Health Services Research in Germany The Input of Transfusion Medicine Prof. Dr. Harald Klüter Institute of Transfusion Medicine and
Surveillance Report 2014
Surveillance Report 2014 Executive summary We are pleased to present the third report for our stakeholders describing infectious disease surveillance. High quality and timely surveillance is key to the
The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P
The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P Record Status This is a critical abstract of an economic evaluation that meets
Overview of the testing strategy stages that the Japanese Red Cross has gone through (HBV, HIV)
2014/LSIF/PD/006 Overview of the Testing Strategy Stages That the Japanese Red Cross (JRC) Has Gone Through (HBV, HIV) - The JRC Approach to Donor Recruitment in the Era of Aging Population Submitted by:
Pathogen inactivation in platelet concentrates in France
Swisstransfusion: Jahrestagung 2011 Fribourg, 8-9 septembre, 2011 Pathogen inactivation in platelet concentrates in France Jean-Pierre Cazenave EFS-Alsace, UMR_S949 INSERM-Université de Strasbourg, France
Screening donors and donations for transfusion transmissible infectious agents. Alan Kitchen
Screening donors and donations for transfusion transmissible infectious agents Alan Kitchen Aim Not to teach you microbiology To provide and awareness of the big picture To provide an understanding of
Fatalities Reported to FDA Following Blood Collection and Transfusion
Fatalities Reported to FDA Following Blood Collection and Transfusion Annual Summary for Fiscal Year 2013 I. Background As mentioned in the previous annual summaries of fatalities reported to the FDA,
Bacterial Contamination of Donor Blood and Blood Components from a Tertiary Care Hospital in North India
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 07 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.707.207
WHO Parvovirus B19 Genotype Panel
WHO Parvovirus B19 Genotype Panel Mei-ying W Yu, PhD SoGAT XXII Rome, 14-15 April 2011 1 st WHO International Reference Panel for Parvovirus B19 Genotypes In Oct 2009, a plasma-derived parvovirus B19 (B19V)
PATHOGEN DETECTION WITH THE FILMARRAY
PATHOGEN DETECTION WITH THE FILMARRAY The System Sample-to-Answer in an Hour Single sample Multiple samples The FilmArray integrates sample preparation, amplification, detection, and analysis all into
KENNEL KARE SC DISINFECTANT / CLEANER / DEODORIZER Efficacy Data EPA Reg. #
Inc. Efficacy: Disinfection (at ½ ounce per gallon) Kennel Kare SC is bactericidal according to the AOAC Use Dilution Test method on hard inanimate surfaces modified in the presence of 5% organic serum
Routine NAT-screening for West Nile Virus Infections in Germany: Being prepared
Routine NAT-screening for West Nile Virus Infections in Germany: Being prepared R. Thermann, W. K. Roth IPFA / PEI 18 th international workshop on Surveillance and screening of blood borne pathogens Budapest,
Keeping the Blood Supply Safe Current and Future Strategies. Marissa Li, MD
Keeping the Blood Supply Safe Current and Future Strategies Marissa Li, MD Overview Pre-collection Donor Screening Collection Visual Inspection Aseptic Processing Leukoreduction of Apheresis Collections
KENNEL KARE SC DISINFECTANT / CLEANER / DEODORIZER Efficacy Data EPA Reg. #
Inc. Efficacy: Hospital Disinfection (at ½ ounce per gallon) Kennel Kare SC is bactericidal according to the AOAC Use Dilution Test method on hard inanimate surfaces modified in the presence of 5% organic
Surveillance Report 2015
Surveillance Report 2015 Executive summary We are pleased to present the fourth report for our stakeholders describing infectious disease surveillance. High quality and timely surveillance is key to the
Transfusion-transmitted Cytomegalovirus
Transfusion-transmitted Cytomegalovirus Can you confidently abandon CMV seronegative products in the modern era of pre-storage leukoreduction? Jeannie Callum, BA, MD, FRCPC Really? Are we still talking
Source Plasma Safety
Source Plasma Safety Plasma May 15-19, 2017 George Schreiber, ScD, PPTA Director, Epidemiology Three components: Plasma Product Safety Donor Quality Manufacturing Pool Quality Fractionation Process Safe
BLOOD SAFETY STATUS IN INDONESIA. Yuyun Soedarmono Chairman of the Indonesian Association of Transfusion Medicine
BLOOD SAFETY STATUS IN INDONESIA Yuyun Soedarmono Chairman of the Indonesian Association of Transfusion Medicine OUTLINE Background Blood services in Indonesia Regulation related to blood safety in Indonesia
Guide to the preparation, use and quality assurance of blood components
Contents Foreword...3 Members of the European Committee (Partial Agreement) on Blood Transfusion... 8 Members of the GTS working group... 22 Members of the TS066 working group... 30 Recommendation No.
Efficacy Data. Disinfectant Cleaner & Odor Counteractant EPA REG. #
SENTS-ALE Hospital Disinfection (at 2 ounces per gallon)) Scents-Able is bactericidal according to the AOA Use Dilution Test method on hard inanimate surfaces modified in the presence of 5% organic serum
Stability of native, lyophilized and inactivated standards
Stability of native, lyophilized and inactivated standards Harry van Drimmelen Bio Quality Control, Heiloo, Netherlands Satellite Meeting before IPFA-PEI 25 th Workshop Twenty-five Years Standardization
605 Springs Road Bedford, MA
EFFICACY DATA FOR BIO-CLEAN (EPA Reg. No. ) VIRUCIDAL DATA: Test Methods: *U.S E.P.A Pesticide Assessment Guidelines, Subdivision G: Product Performance, Section 91-2(f), and Section 91-30 (d),(e), November,
Be ready. The INTERCEPT Blood System for Platelets and Plasma pathogen reduction system
Be ready. The INTERCEPT Blood System for Platelets and Plasma pathogen reduction system INTERCEPT Blood System for Platelets an Blood safety is changing Safe donated blood is critical to improving certain
Keeping blood transfusions safe:
ISP-WIV Seminar Diagnosis and surveillance of infectious diseases May 18 th, 2017 Keeping blood transfusions safe: the challenge of emerging infectious diseases Presented by Roland HÜBNER Superior Health
Surveillance Report 2016
Surveillance Report 2016 Executive summary We are pleased to present the fifth report for our stakeholders describing infectious disease surveillance. High quality and timely surveillance is key to the
TRANSFUSION ASSOCIATED DISEASE, RECALL, OR COMPLICATION INVESTIGATION POLICY I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION:
I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION: A. TRANSFUSION RELATED FATALITY: FDA and MEDIC must be notified immediately, and subsequently in writing, when a possible transfusion related
Blood Transfusion. What is blood transfusion? What are blood banks? When is a blood transfusion needed? Who can donate blood?
What is blood transfusion? A blood transfusion is a safe, common procedure in which blood is given through an intravenous (IV) line in one of the blood vessels. A blood transfusion usually takes two to
Evaluation of the feasibility of the VACUETTE Urine CCM tube for microbial testing of urine samples
Evaluation of the feasibility of the VACUETTE Urine CCM tube for microbial testing of urine samples Background The VACUETTE Urine CCM tube is for the collection, transport and storage of urine samples
HBV-DNA reference panels
HBV-DNA reference panels The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Overview HBV-DNA panels
INDONESIAN EXPERIENCE IN PRODUCING MINIPOOL CRYOPRECIPITATE. Yuyun SM Soedarmono
INDONESIAN EXPERIENCE IN PRODUCING MINIPOOL CRYOPRECIPITATE Yuyun SM Soedarmono 1 BACKGROUND Indonesia has more than 240 million population and approximately 25,000 hemophilia A patients Hemophilia A patients
Microsan rx Anti-Microbial Healthcare Professional Soap. Organism Positives ATCC #
: Contact Time: 30 seconds 17,500 ppm. PCMX active Organism Positives ATCC # Acinetobacter calcoaceticus var. anitratus 0 s Acinetobacter calcoaceticus var. woffii 0 s Actinobacillus pleuropneumonia 0
NEUTRAL GERMICIDAL CLEANER
NEUTRL GERMIIDL LENER Disinfectant leaner Mildewstat Fungicide Deodorizer Virucide* Neutral Germicidal leaner is a nonalkaline disinfectant that cleans and deodorizes in one step. It is formulated to a
2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies
2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies Submitted by: Malaysia Policy Dialogue and Workshop on Attaining a Safe and Sustainable Blood Supply Chain Manila, Philippines 30 September 1
Bacterial infections transmitted by blood transfusion
T R A N S F U S I O N C O M P L I C A T I O N S TRANSFUSION-TRANSMITTED INFECTION IN THE U.S. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000 Matthew J. Kuehnert, Virginia
Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India.
Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India. Cinzia Keechilot, Veena Shenoy 1,V Anil kumar 2,Lalita Biswas 3. MBBS student * Transfusion
Laboratory reports of hepatitis A and C infection in England and Wales: January to March
Volume 4 29 Published on: 23 July 2010 Current News Increased diagnoses of HIV infection in the over-50s in UK Infection Reports Immunisation Laboratory reports of hepatitis A and C infection in England
Using Donor Human Milk in Extremely Premature Infants
Using Donor Human Milk in Extremely Premature Infants Introduction Scott Eaker, Vice President of Quality and Regulatory Affairs Scott Elster, Chief Executive Officer David Rechtman, MD, Chief Medical
Protocols for Laboratory Verification of Performance of the BioFire FilmArray Pneumonia Panel
Protocols for Laboratory Verification of Performance of the BioFire FilmArray Pneumonia Panel Laboratory Protocols for Use with a ZeptoMetrix NATtrol Verification Panel Purpose The Clinical Laboratory
P0141 HBV 1000 copies/ml genotype reference panel
P0141 HBV 1000 copies/ml genotype reference panel P0141 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents
Hemovigilance: bacterial problems. J. Wiersum Osselton, A. v.tilborgh, J. Marcelis, TRIP colleagues and all hospital hemovigilance staff
Hemovigilance: bacterial problems J. Wiersum Osselton, A. v.tilborgh, J. Marcelis, TRIP colleagues and all hospital hemovigilance staff TRIP definitions 2003 7 Non hemolytic febrile transfusion reaction
HYPOCHLOROUS ACID (HOCl) Our Body's immune system protector in a BOTTLE
AQUAOX IS A REVOLUTIONARY DISINFECTION SOLUTION WHICH ACTIVE INGREDIENT HOCL IS NON HAZARDOUS, HAS NO FRAGRANCE, AND IS SAFE ON ALL SURFACES (AND ON SKIN.) HYPOCHLOROUS ACID (HOCl) Our Body's immune system
MICROBIOLOGICAL PROFILE
Evans Vanodine International plc G L O B A L H Y G I E N E S O L U T I O N S HANDSAN MICROBIOLOGICAL PROFILE 2 INTRODUCTION HANDSAN is a ready to use, quick acting and highly effective, alcohol based hygienic
INFECTIOUS DISEASE. Page 2
Infectious disease Advantages OF TESTING INFECTIOUS DISEASE We are in the middle of a paradigm shift in infectious disease diagnostic testing. As we move from targeted infectious disease testing to a syndromic
risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV)
Prevention and ResidualR risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV) Syria Laperche L (Centre National de référence r rence pour les hépatites h B et C en Transfusion)
WHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA
ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 21 October 2016 WHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA
Questions and Answers about
Questions and Answers about What is PRO TEX TM Alcohol-Free, Foam Hand & Skin Sanitizer? PRO TEX TM Alcohol-Free, Foam Hand & Skin Sanitizer, based on the active ingredient Benzalkonium chloride, is a
point-of-care test (POCT) Definition: an analytical or diagnostic test undertaken in a setting distinct from a normal hospital or non-hospital
point-of-care test (POCT) Definition: an analytical or diagnostic test undertaken in a setting distinct from a normal hospital or non-hospital laboratory performed by a health care professional or non-medical
Chain of Infection Agent Mode of transmission Contact (direct, indirect, droplet spread) Airborne Common-vehicle spread Host
Goals Microbiology of Healthcare-associated Infections William A. Rutala, Ph.D., M.P.H. Director, Statewide Program for Infection Control and Epidemiology and Research Professor of Medicine, University
A tool for improving blood transfusion safety? Lessons from 15 years of hemovigilance in France
A tool for improving blood transfusion safety? Lessons from 15 years of hemovigilance in France Georges Andreu Institut National de la Transfusion Sanguine G. Andreu, INTS TRIP Bussum 2008 11 27 1 Hemovigilance
The testing of Donated Blood and Components at NHSBT
The testing of Donated Blood and Components at NHSBT NHSBT is responsible for collecting all donated blood and platelets in England, then processing into components before issuing to client hospitals.
Protocols for Laboratory Verification of Performance of the BioFire FilmArray Pneumonia Panel plus
Protocols for Laboratory Verification of Performance of the BioFire FilmArray Pneumonia Panel plus Laboratory Protocols for Use with a ZeptoMetrix NATtrol Verification Panel Purpose The Clinical Laboratory
HEV Assay Development Update
HEV Assay Development Update Jeffrey M. Linnen, Ph.D. Senior Director, Research & Development Hologic Gen-Probe, San Diego, California USA IPFA/PEI 20th International Workshop on Surveillance and Screening
Trends in molecular diagnostics
Trends in molecular diagnostics Detection of target genes of interest Quantification Infectious diseases HIV Hepatitis C & B TB / MAC Cytomegalovirus Herpes simplex Varicella zoster CT/GC HPV Profiling
Guidance for Industry
Guidance for Industry Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components (including Source Plasma and Source Leukocytes) to Adequately and Appropriately
Objectives. Methods. Results. Economic
Octaplas Compared with Fresh Frozen Plasma to Reduce the Risk of Transmitting Lipid-Enveloped Viruses: An Economic Analysis and Budget Impact Analysis [Adapted from Membe SK, Coyle D, Husereau D, Cimon
ONE STEP (Lemon, Mint, Pine) Detergent for Cleaning, Disinfecting and Deodorizing
SUMMARY OF ANTIMICROBIAL ACTIVITY ONE STEP (Lemon, Mint, Pine) Detergent for Cleaning, Disinfecting and Deodorizing Description One Step is an effective economical 4 ounce per gallon disinfectant, specifically
CAVIWIPES1. Technical Bulletin
CAVIWIPES1 Technical Bulletin CaviWipes1 Disinfecting Towelettes are non-woven disposable towelettes pre-saturated with CaviCide1. CaviWipes 1 are intended for use in health care settings such as hospitals,
Neutral Germicidal Cleaner
TM Neutral Germicidal leaner Neutral Germicidal leaner is a nonalkaline disinfectant that cleans and deodorizes in one step. It is formulated to a neutral ph which will not dull high gloss floor finishes
Instruction to implement measures for risk minimisation in using HIV-1 NAT test systems
Paul-Ehrlich-Institut P.O. Box 63207 Langen, Germany To: The marketing authorisation holders of cellular blood products and fresh frozen plasma and the holders of authorisations for stem cell preparations
Situation of XMRV and Blood Transfusion. Celso Bianco, MD ISBT Working Party on TTID Lisbon, June 19, 2011
Situation of XMRV and Blood Transfusion Celso Bianco, MD ISBT Working Party on TTID Lisbon, June 19, 2011 Lombardi et al. Science 326, 585 (2009) Conclusions: CFS and XMRV XMRV found in 67% of CFS patients
Outbreak investigation of nosocomial infections
Definitions Outbreak investigation of nosocomial infections School of Public Health, HSUM March 2012 Walter Popp, University Clinics Essen, Germany Epidemia increased number of cases, limited in time and
Potential Reimbursement CPT Codes
BioFire FilmArray Blood Culture Identification (BCID) Panel Medicare All targets (n) 87150 n x * *BioFire BCID Panel is comprised of 27 total targets. The number of targets allowed for reimbursement may
Healthcare- Associated Infections: Preventing the Preventable
Healthcare- Associated Infections: Preventing the Preventable HEALTHCARE-ASSOCIATED INFECTIONS: PREVENTING THE PREVENTABLE Course # 516 5 CE Hours Author: Diana Harland, BS, CCRC, Editor: Cheryl Duksta,
The Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
Fresh Citrus Disinfectant Cleaner
SUMMARY OF ANTIMICROBIAL ACTIVITY Fresh Citrus Disinfectant Cleaner Description Fresh Citrus Disinfectant Cleaner is an effective economical 4 ounce per gallon disinfectant, specifically designed for hospitals,
HIV-RNA reference panels
The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Overview HIV-RNA panels for sensitivity analysis...
Standardization: Calibration of. International Standards, reference preparations and working standards. Micha Nübling, PEI
Standardization: Calibration of International Standards, reference preparations and working standards Micha Nübling, PEI Paul-Ehrlich-Institut Governmental Authority for biological medicinal products Blood
Transfusion-transmitted HIV from seroconverted blood donors has not been identified in England since the introduction of HIV NAT screening
Transfusion-transmitted HIV from seroconverted blood donors has not been identified in England since the introduction of HIV NAT screening Bhavita Vishram Timeline of introduction of microbiological tests
Quantification of HBV, HCV genotype and HIV subtype panels
Quantification of HBV, HCV genotype and HIV subtype panels Harry van Drimmelen 1,2, Wim Quint 2, Nico Lelie 3 and the international NAT study group 1. Biologicals Quality Control, 2. DDL Diagnostic Laboratory,
Chapter 08 Lecture Outline
Chapter 08 Lecture Outline See separate PowerPoint slides for all figures and tables preinserted into PowerPoint without notes. Copyright 2016 McGraw-Hill Education. Permission required for reproduction
Human diagnostics. Better be Sure: Quantify HDV & HBV viral load. RoboGene product family
Human diagnostics Better be Sure: Quantify HDV & HBV viral load. RoboGene product family 2 RoboGene Product Family Improved patient management: Standardized monitoring of HBV DNA and HDV RNA viral load.
Questions for Posters #1-19:
POSTER #1: Questions for Posters #1-19: 1. Bacterial load in urine samples was performed by assessing: a. Copy numbers of 16s RNA sequences of bacteria b. Copy numbers of whole genome sequencing of bacteria
Purification of viral nucleic acid from serum, plasma, cell-free biological fluids MACHEREY- NAGEL
Purification of viral nucleic acid from serum, plasma, cell-free biological fluids Purification of viral nucleic acid from serum, plasma, cell-free biological fluids viral RNA: viral DNA: NucleoSpin RNA
TECHNICAL BULLETIN PURELL Foodservice Surface Sanitizer
Product Description: TECHNICAL BULLETIN PURELL Foodservice Surface Sanitizer EPA-Registered PURELL Foodservice Surface Sanitizer is no-rinse food contact surface sanitizer designed to kill the most relevant
Experience with Standardisation of Blood Virology NAT. Clare Morris Division of Retrovirology National Institute for Biological Standards and Control
Experience with Standardisation of Blood Virology NAT Clare Morris Division of Retrovirology National Institute for Biological Standards and Control Background of Blood Virology Standardisation In the
Evaluation of run controls for cobas 6800 MPX and HEV assay
Evaluation of run controls for cobas 6800 MPX and HEV assay Marco Koppelman Head of Nucleic Acid testing (NAT) laboratory, National Screening laboratory of Sanquin (NSS) in the Netherlands Satellite Meeting
Practical Aspects of Standardisation for a Global Controls Manufacturer
Practical Aspects of Standardisation for a Global Controls Manufacturer MRSA SoGAT Clinical Diagnostic Meeting NIBSC, UK June 25, 2008 Frank Opdam PhD, AcroMetrix Standardisation A fundamental goal of
M O L E C U L A R G E N E T I C S
MOLECULAR GENETICS ADVANTAGES OF MOLECULAR GENETICS Molecular genetics is a dynamic and transformative area of diagnostics, leading to insights in research and treatment in many disease states that are
Abena Antimicrobial Glove
Abena Antimicrobial Glove Revolutionizing the world of infection prevention The first non-leaching antimicrobial nitrile glove Provides active protection against HAIs Kills up to 99.999% of selected bacteria
Transfusion transmitted infections in National Haemovigilance Systems: the Greek experience
Transfusion transmitted infections in National Haemovigilance Systems: the Greek experience Global blood product safety 10 April 2019, Rome, Italy Constantina Politis National Coordinating Haemovigilance
Impact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013
Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013 Overview of SANBS SANBS is a private not for profit company
Lookback studies to assess viral risks The French experience
Lookback studies to assess viral risks The French experience 2000-2012 S Laperche 1, MF Leconte des Floris 2, J Pillonel 3, L Hauser 2, C Lefort 2, JY Py 2, I Hervé 2, R Djoudi 2 For the French haemovigilance